Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review DOI Creative Commons
Yan Li,

Zhengchao Zhang,

Ting Wang

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Sept. 1, 2023

Prostate cancer (PCa) is a serious threat to the health of men all over world. The progression PCa varies greatly among different individuals. In clinical practice, some patients often progress advanced PCa. Therefore, accurate imaging for diagnosis and staging particularly important management patients. Conventional examinations such as MRI CT cannot accurately diagnose pathological stages PCa, especially metastatic lymph node (LN) stages. As result, developing an molecular targeted crucial specific membrane antigen (PSMA) great value in because its expression At present, researchers have developed positron emission tomography (PET) targeting PSMA. A large number studies confirmed that it not only has higher tumor detection rate, but also diagnostic efficacy stage compared with traditional methods. This review summarizes recent on PSMA PET diagnosis, analyzes detail, provides new ideas urological clinicians management.

Language: Английский

Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis DOI Creative Commons
Barbara Muoio, Domenico Albano, Francesco Dondi

et al.

Diagnostics, Journal Year: 2022, Volume and Issue: 12(7), P. 1665 - 1665

Published: July 8, 2022

Background: Several studies proposed the use of positron emission tomography (PET) with Prostate Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in brain tumors. Our aim is to calculate diagnostic accuracy these methods high-grade gliomas (HGG) a bivariate meta-analysis. Methods: A comprehensive literature search on PET/CT or PET/MRI PSMA-targeting HGG was performed. Original articles evaluating imaging both differential diagnosis between and low-grade (LGG) assessment suspicious recurrence were included. Pooled sensitivity, specificity, positive negative likelihood ratios (LR+ LR-), odds ratio (DOR) including 95% confidence intervals (95% CI) calculated. Statistical heterogeneity also assessed using I2 test. Results: The meta-analysis six selected (157 patients) provided following results about HGG: sensitivity 98.2% CI: 75.3–99.9%), specificity 91.2% 68.4–98.1%), LR+ 4.5 2.2–9.3), LR− 0.07 0.04–0.15), DOR 70.1 19.6–250.9). No significant statistical among included found (I2 = 0%). Conclusions: quantitative data demonstrate high for detection. However, more are needed confirm promising role PSMA-targeted PET this clinical setting.

Language: Английский

Citations

22
Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer DOI Creative Commons
Costantina Maisto, Michela Aurilio,

Anna Morisco

et al.

Molecules, Journal Year: 2022, Volume and Issue: 27(12), P. 3862 - 3862

Published: June 16, 2022

The aim of this work is to compare [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times costs the radiolabeling process, features including pharmacokinetics, impact on patient management. analysis advantages drawbacks both radioligands might help make a better choice based firm data. For [68Ga]Ga-PSMA-11, radiochemical yield (RCY) using low starting activity (L, average 596.55 ± 37.97 MBq) was 80.98 0.05%, while high one (H, 1436.27 68.68 MBq), RCY 71.48 0.04%. Thus, increased activities [68Ga]-chloride negatively influenced RCY. A similar scenario occurred for [18F]PSMA-1007. rate detection PCa lesions Positron Emission Tomography/Computed Tomography (PET/CT) radioligands, their distribution normal organs significantly differed. Furthermore, patterns biodistribution found among [18F]PSMA-1007, [177Lu]Lu-PSMA-617, most used agent RLT. Moreover, economical aspects each single batch production corrected number allowed examinations suggested major compared [68Ga]Ga-PSMA-11. Data from study should support proper selection PSMA PET radioligand use basis cases study.

Language: Английский

Citations

20
H19in Serum Extracellular Vesicles Reflects Resistance to AR Axis-targeted Therapy Among CRPC Patients DOI Open Access
Taku Kato, Kyojiro Kawakami, Kosuke Mizutani

et al.

Cancer Genomics & Proteomics, Journal Year: 2023, Volume and Issue: 20(5), P. 456 - 468

Published: Jan. 1, 2023

Abstract

Background/Aim: We aimed to evaluate the changes of androgen receptor (AR) signaling-related long non-coding RNAs (lncRNAs) in serum extracellular vesicles (EVs) from prostate cancer (PC) patients, order identify novel biomarkers for AR axis-targeted therapy (ARAT)-resistance among castration-resistant PC (CRPC) patients. Patients and Methods: EVs were isolated 2 patients before after acquiring ARAT-resistance. RNA profiling was performed by RNA-sequencing. The expression levels selected lncRNAs analyzed digital droplet PCR (ddPCR) 58 localized 14 metastatic at diagnosis, 7 ARAT-naïve 6 ARAT-resistant CRPC LncRNA H19 tissue examined using published data. In analyze role H19, prognosis proteomic analysis 22Rv1 cells. Results: RNA-sequencing revealed that AR-regulated most enriched Among them, up-regulation (PCAT1, HOXA-11AS, ZEB1-AS1, ARLNC1, PART1, CTBP1-AS PCA3) confirmed ddPCR. contained (EV-H19) significantly increased compared or tissue, negatively correlated with protein AR-activity score up-regulated neuroendocrine low expression. Furthermore, EV-H19 associated worse outcome androgen-deprivation therapy. Proteomic demonstrated knockdown enhanced PC-related Conclusion: may correlate AR-signaling activity could be a marker diagnose ARAT-resistance

Language: Английский

Citations

11
Preparation, Biological Evaluation, and First-in-Human Single-Photon Emission Computed Tomography (SPECT) Study of 99mTc-Labeled Prostate-Specific Membrane Antigen (PSMA)-Targeted Radiotracers Containing Triazole with Reduced Kidneys Accumulation DOI Open Access
Di Xiao,

Peiwen Han,

Yuhao Jiang

et al.

ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(5), P. 1335 - 1347

Published: April 10, 2024

Prostate-specific membrane antigen (PSMA), a well-established biological marker for prostate cancer (PCa) imaging and therapy, is overexpressed on the surface of lesions. In this study, triazole ring was introduced into linker by click chemistry to generate HYNIC-derived ligand (

Language: Английский

Citations

4
Practical Approaches to Advancing Health Equity in Radiology, From theAJRSpecial Series on DEI DOI

Nikki López-Suárez,

Peter Abraham,

Madeline Carney

et al.

American Journal of Roentgenology, Journal Year: 2023, Volume and Issue: 221(1), P. 1 - 10

Published: Jan. 11, 2023

Despite significant advances in health care, many patients from medically under-served populations are impacted by existing care disparities. Radiologists uniquely positioned to decrease disparities and advance equity efforts their practices. However, literature on practical tools for advancing radiology applicable a wide variety of patient settings is lacking. Therefore, this article seeks equip radiologists with an evidence-based knowledge tool kit strategies, presented terms four pillars research, clinical education, innovation. For each pillar, across diverse practice examined through the lens barriers, current best practices, future directions, incorporating examples relevant spectrum populations. Health provide opportune window transform personalized delivery that responsive needs. Guided compassion empathy as core principles equity, helpful framework step toward social justice health.

Language: Английский

Citations

10
Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics DOI Creative Commons
Olga V. Sergeeva, Liang Luo, Anthony Guiseppi‐Elie

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 17, 2025

Cancer continues to be one of the leading causes death worldwide, and conventional cancer therapies such as chemotherapy, radiation therapy, surgery have limitations. RNA therapy vaccines hold considerable promise an alternative for their ability enable personalized with improved efficacy reduced side effects. The principal approach is induce a specific immune response against cells. However, major challenge in immunotherapy predict which patients will respond treatment monitor vaccine during treatment. Theragnostics, integration diagnostic therapeutic capabilities into single hybrid platform system, has potential address these challenges by enabling real-time monitoring while allowing endogenously controlled adjustments. In this article, we review current state-of-the-art theragnostics including imaging agents, biomarkers, other tools relevant cancer, application development personalization. We also discuss opportunities further clinical translation vaccines.

Language: Английский

Citations

0
Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B DOI Creative Commons

Lawrence Saperstein,

Steven P. Rowe, Michael A. Gorin

et al.

The Prostate, Journal Year: 2025, Volume and Issue: unknown

Published: May 4, 2025

ABSTRACT Background This study investigates the impact of hormone therapy (HT) on diagnostic performance 18 F‐piflufolastat PET/CT in OSPREY (NCT02981368) cohort B patients with recurrent or metastatic prostate cancer. Methods was evaluated ( n = 117 men) elevated prostate‐specific antigen (PSA) levels and suspected local recurrence disease baseline conventional imaging. Patients were stratified based HT status, sensitivity positive predictive value (PPV) determined for subset 93 evaluable pathology. Baseline serum PSA testosterone within 30 days before dosing using standardized laboratory methods. Results In B, 34.4% (32/93) at least one concomitant a median exposure duration 15.5 months. The concurrent 32) 31.6 ng/mL 9 ng/dL, respectively. For not 61), 6.1 317.35 across three readers 96.4% (95%CI: 80.8%–100%) receiving 95.4% 83.7%–99.6%) HT. A modest increase PPV observed (median readers: 90.0% [95%CI: 73.6, 97.3]) compared to 77.4% 66.1, 88.6]). Conclusions unaffected by and/or

Language: Английский

Citations

0
Primary Staging of Prostate Cancer Patients with [18F]PSMA-1007 PET/CT Compared with [68Ga]Ga-PSMA-11 PET/CT DOI Open Access
Manuela A. Hoffmann,

Jonas Müller-Hübenthal,

Florian Rosar

et al.

Journal of Clinical Medicine, Journal Year: 2022, Volume and Issue: 11(17), P. 5064 - 5064

Published: Aug. 29, 2022

Hybrid imaging with prostate-specific membrane antigen (PSMA) is gaining importance as an increasingly meaningful tool for prostate cancer (PC) diagnostics and a guide therapy decisions. This study aims to investigate compare the performance of [18F]PSMA-1007 (18F-PSMA) [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography (68Ga-PSMA) in initial staging PC patients.The data 88 biopsy-proven patients were retrospectively evaluated. PSMA-avid lesions compared histopathologic Gleason Score (GS) biopsies, results plotted by receiver operating characteristic (ROC)-curve. Optimal maximum standardized uptake value (SUVmax) cut-off values rated using Youden index.18F-PSMA was able distinguish GS ≤ 7a from ≥7b sensitivity 62%, specificity 85%, positive predictive (PPV) 92%, accuracy 67% SUVmax 8.95, whereas 54%, 91%, PPV 93%, 66% 68Ga-PSMA (SUVmax 8.7).Both methods demonstrated high concordance detected histopathologically proven PC. 18F-PSMA are both suitable characterization primary comparable correlation GS. Neither method showed superior advantage. Our calculated thresholds may represent valuable parameters clinical use clinically significant (csPC) non-csPC.

Language: Английский

Citations

16
Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors DOI Creative Commons
Jisce R. Puik,

Chung Thanh Le,

Geert Kazemier

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 205, P. 104556 - 104556

Published: Nov. 17, 2024

Prostate-specific membrane antigen (PSMA) is one of the few biomarkers which has been successfully translated to clinic as theranostic biomarker for patients with prostate cancer. In context cancer, PSMA overexpressed on cell tumor cells, making it a viable target interventions urea-based small molecule inhibitors or antibodies conjugated radioactive isotopes. Interestingly, in several non-prostatic cancers, expression appears be associated neovasculature. This offers novel therapeutic opportunities treatments targeting vasculature cancers. this review, we discuss and its potential vasculature-directed approaches, including radioligand therapy, fusion protein vaccination CAR T-cell therapy.

Language: Английский

Citations

2
Expression of PSMA in Tumor-Associated Vasculature Predicts Poorer Survival in Patients With Hepatocellular Carcinoma and Is Likely Associated With PD-L1 DOI

Rena X. Li,

Yansheng Hao, Mark Ettel

et al.

International Journal of Surgical Pathology, Journal Year: 2024, Volume and Issue: 32(7), P. 1248 - 1255

Published: Feb. 6, 2024

PSMA (prostate-specific membrane antigen) is a type II transmembrane glycoprotein recently found to be expressed in hepatocellular carcinoma (HCC). We aimed characterize the expression pattern of HCC and its association with clinicopathologic parameters other biomarkers.

Language: Английский

Citations

2